Gilead Sciences has reported positive data from analysis of an international cohort of patients treated with remdesivir as a potential treatment for Covid-19.

The analysis reviewed 53 patients who were hospitalised with severe complications related to the novel coronavirus infection in the US, Europe, Canada and Japan.

Patients received the experimental antiviral drug on an individual compassionate use basis.

Read the full article here